ROPIVACAINE
Arterial Occlusive Diseases
University of Sao Paulo General HospitalSmall moleculePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
8 Active assets in the Arterial Occlusive Diseases cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
3-N-BUTYLPHTHALIDE The Second Hospital of Hebei Medical University | Phase 4 | BB |
Recombinant Human Plasminogen Activator The First Affiliated Hospital with Nanjing Medical University | Phase 3 | B |
Tenecteplase Beijing Tiantan Hospital | Phase 3 | B |
WARFARIN Columbia University | Phase 3 | B |
Apixaban Columbia University | Phase 3 | B |
View all 10 →
Same molecule, other indications
ROPIVACAINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →